Hydrocortison Vuab (Hydrocortisone)

Hydrocortison Vuab is used in clinical settings where rapid systemic glucocorticoid activity is required.

• Management of acute adrenal crisis or secondary adrenal insufficiency.
• Treatment of severe allergic reactions, including anaphylaxis.
• Control of inflammatory disorders such as rheumatoid arthritis flare or systemic lupus erythematosus.
• Adjunct therapy for asthma exacerbations or chronic obstructive pulmonary disease (COPD) requiring systemic steroids.
• Supportive care in extensive dermatologic inflammation.
• Emergency management of septic shock when corticosteroid supplementation is indicated.

• Hydrocortison Vuab delivers hydrocortisone, a synthetic analogue of endogenous cortisol, which binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements, altering transcription of target genes. This results in decreased synthesis of pro‑inflammatory mediators such as prostaglandins and leukotrienes, inhibition of immune cell activation, and promotion of anti‑inflammatory protein expression, producing systemic glucocorticoid effects.

Adverse reactions to Hydrocortison Vuab may vary in frequency and severity, ranging from mild, transient symptoms to rare but serious events.

Common

• Injection‑site pain, erythema, or swelling that usually resolves within a few hours.
• Transient elevation of blood glucose levels, which may be more pronounced in patients with pre‑existing diabetes.
• Fluid retention leading to mild weight gain, peripheral edema, or a feeling of bloating.
• Mood alterations such as irritability, anxiety, or insomnia, often temporary and dose‑related.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal axis, which can result in secondary adrenal insufficiency after abrupt discontinuation.
• Development of Cushingoid features with prolonged use, including central obesity, facial rounding, and skin thinning.
• Severe hypertension or electrolyte disturbances such as hypokalemia, which may require medical monitoring.

When prescribing Hydrocortison Vuab, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

• Assess for existing infections before initiating therapy.
• Evaluate blood glucose and electrolyte status, especially in patients with diabetes or renal disease.
• Use the lowest effective dose for the shortest duration possible.
• Monitor for signs of adrenal suppression during tapering or after discontinuation.
• Avoid abrupt cessation after prolonged therapy to prevent adrenal crisis.
• Consider potential contraindications such as systemic fungal infections or uncontrolled hypertension.
• Inform patients about the possibility of increased susceptibility to infection and advise them to report signs promptly.

Hydrocortison Vuab can interact with other medications, altering its efficacy or increasing the risk of adverse effects.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) that may markedly reduce hydrocortisone plasma concentrations and therapeutic effect.
• Simultaneous administration with systemic anticoagulants (e.g., warfarin) without close monitoring, as glucocorticoids may enhance bleeding tendency and complicate anticoagulation control.

Use with caution

• Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration, especially in patients with a history of peptic disease.
• Combining with other immunosuppressants (e.g., azathioprine, cyclosporine, methotrexate) may potentiate overall immunosuppression and raise infection susceptibility.
• Use together with diuretics cautiously, as fluid retention from steroids can exacerbate electrolyte imbalances, particularly hypokalemia and sodium retention.